Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013142 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01013142 is a Phase 1 study that has completed, run by MediciNova. The registered enrollment target is 48 participants.
The verdict
NCT01013142, a Phase 1 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.
Interventions
- DRUG MN-221 (Dose Group 1)
- DRUG MN-221 (Dose Group 2)
- DRUG MN-221 (Dose Group 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013142
The ClinicalTrials.gov registry entry for NCT01013142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MN-221 (Dose Group 1) is the first listed.
NCT01013142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013142 about?
NCT01013142 is a clinical study titled "Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.
What is the current status of trial NCT01013142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2009-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01013142?
The interventions under investigation include: MN-221 (Dose Group 1) (DRUG), MN-221 (Dose Group 2) (DRUG), MN-221 (Dose Group 3) (DRUG).
Who is sponsoring clinical trial NCT01013142?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.